Intermittent versus daily therapy for treating tuberculosis in children

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Bose, Anuradha ^a   Kalita, Soumik ^b   Rose, Winsley ^a   Tharyan, Prathap ^c  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ALL CAUSE MORTALITY; CHILDHOOD DISEASE; COMPARATIVE EFFECTIVENESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; HEPATITIS; HUMAN; JAUNDICE; LIVER TOXICITY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; VOMITING; ADOLESCENT; CHILD; DRUG ADMINISTRATION; LUNG TUBERCULOSIS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS, PULMONARY;

EID: 84903756577     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007953.pub2     Document Type: Review

References (118)

1. Kansoy S, Kurtaş N, Akşít S, Aksoylar S, Yaprak I, Çağlayan S. Superiority of intermittent-short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences 1996;26(1):41-3.
2. Kumar L, Dhand R, Singhi PD, Rao KL, Katariya S. A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal 1990;9(11):802-6.
3. Ramachandran P, Kripasankar A S, Duraipandian M. Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis 1998;45:83-7.
4. Te Water Naude JM, Donald PR, Hussey GD, Kipel MA, Louw A, Perkins DR, et al.Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal 2000;19(5):405-10.
5. Al-Dossary FS, Ong LT, Correa AG, Starke JR. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy. Pediatric Infectious Disease Journal 2002;21(2):91-7.
6. Amrane R, Mazouni L, Boulahbal F, Abtroun N, Zidane, C . A controlled survey comparing 2 short-term therapeutic regimes in lymph node tuberculosis [Enquête contrôlée comparant deux régimes thérapeutiques de courte durée dans la tuberculose ganglionnaire]. Revue Des Maladies Respiratoires 1989;6(1):53-7.
7. Anastasatu C, Anastasatu O, Murgoci G, Dobre M, Bîscă N, Calciu M, et al.The late results of short-term chemotherapy in benign forms of tuberculosis in children. Pneumoftiziologia 1991;40(4):7-9.
8. Anastasatu C, Anastasatu O, Murgoci G, Dobre M. The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children [Rezultatele tardive ale chimioterapiei intensive (9 luni) în formele grave de tuberculoză la copil]. Pneumoftiziologia 1993;42(4):9-12.
9. Balasubramanian R, Sivasubramanian S, Vijayan VK, Ramachandran R, Jawahar MS, Paramasivan CN, et al.Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tubercle 1990;71(4):253-8.
10. Bignall JR. [Controlled therapeutic study of 5 intermittent chemotherapy regimens for pulmonary tuberculosis. 4th international study of the UICT]. Bulletin of the International Union against Tuberculosis 1974;49(1):422-6.
11. Carter S. Primary tuberculosis in African children and the value of isoniazid in treatment. East African Medical Journal 1954;31(6):265-76.
12. Comstock GW, Hammes LM, Pio A. Isoniazid prophylaxis in Alaskan Boarding schools. A comparison of two doses. American Review of Respiratory Disease 1969;100(6):773-9.
13. Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis?. American Review of Respiratory Disease 1970;101(5):780-2.
14. Debre R, Perdrizet S, Lotte A, Naveau M, Lert F. Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. International Journal of Epidemiology 1973;2(2):153-60.
15. Dingley HB, Sehgal KL. Treatment of pulmonary tuberculosis in children--a controlled study. Indian Pediatrics 1974;11(4):289-95.
16. Dingley HB. Short term chemotherapy in children: Three years follow up. Indian Journal of Tuberculosis 1982;29(1):48-54.
17. Eule H, Beck H, Evers H, Fischer P, Kwiatkowski H, Merkel S, et al.Daily ultrashort chemotherapy and intermittent short-term chemotherapy with 4 drugs of communicable pulmonary tuberculosis treated for the first time. Results of a cooperative multicenter study. Zeitschrift für Erkrankungen der Atmungsorgane 1986;167(1-2):29-41.
18. Ganguin HG, Cramer G, Götz J, Holzhauer H, Niegsch G, Sieler H, et al.Proceedings: Results of a controlled trial of intermittent ambulatory therapy of infectious pulmonary tuberculosis with comparison of various maintenance regimens. Zeitschrift für Erkrankungen der Atmungsorgane mit Folia Bronchologica 1973;138(1):107-15.
19. Garciá López JR, Vidal López ML, Castán Vidal ML, Borque Andrés C, de José Gómez MI, García Hortelano J. Short term treatment of infantile pulmonary tuberculosis [Tratamiento de corta duración de la tuberculosis pulmonar infantil]. Anales Españoles De Pediatría 1989;31(2):110-3.
20. Göçmen A, Özçelic U, Kiper M, Toppare M, Kaya S, Cengizlier R, et al.Short course intermittent chemotherapy in childhood tuberculosis. Infection 1993;21(5):324-7.
21. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months.. American Review of Respiratory Diseases 1991;143(4 Pt 1):700-6.
22. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Tubercle 1975;56(2):81-96.
23. Jawahar MS, Sivasubramanian S, Vijayan VK, Ramakrishnan CV, Paramasivan CN, Selvakumar V, et al.Short course chemotherapy for tuberculous lymphadenitis in children. BMJ 1990;301(6748):359-62.
24. Jawahar MS, Rajaram K, Sivasubramanian S, Paramasivan CN, Chandrasekar K, Kamaludeen MN, et al.Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens. Tropical Medicine & International Health 2005;10(11):1090-8. [PUBMED: 16262733]
25. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364(9441):1244-51.
26. Karam-Bechara J, Naime-Libien JE, Posada-Maldonado EE, Aroch-Calderón A, Olvera R. Treatment of tuberculosis in 100 children. A 5-year follow-up [Tratamiento de tuberculosis en 100 niños. Seguimiento durante cinco años]. Salud Pública De México 1994;36(1):30-5.
27. Medical Research Council Working Party on Tuberculosis of the Spine. Controlled trial of short-course regimens of chemotherapy in the ambulatory treatment of spinal tuberculosis. Results at three years of a study in Korea. Twelfth report of the Medical Research Council Working Party on Tuberculosis of the Spine. Journal of Bone and Joint Surgery. British Volume 1993;75(2):240-8.
28. No authors listed. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969;50(2):81-114.
29. No authors listed. A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong: second report:-the results at 12 months. Tubercle 1974;55(3):193-210.
30. No authors listed. A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland. Tubercle 1975;56(1):1-26.
31. No authors listed. A study of two twice-weekly and once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment. 1. First report: the results at 18 months. Tubercle 1976;57(4):235-49.
32. No authors. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months. American Review of Respiratory Diseases 1977;116(5):807-20.
33. No authors listed. A study of two twice-weekly and a once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment. 2. Second report: the results at 36 months. Tubercle 1977;58(3):129-36.
34. No authors listed. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis--a controlled trial of our regimens. Tubercle 1981;62(1):13-29.
35. Rajeswari R, Sivasubramanian S, Balambal R, Parthasarathy R, Ranjani R, Santha T, et al.A controlled clinical trial of short-course chemotherapy for tuberculoma of the brain. Tubercle and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease. 1995;76(4):311-7.
36. Ramachandran P, Duraipandian M, Nagarajan M, Prabhakar R, Ramakrishnan CV, Tripathy SP. Three chemotherapy studies of tuberculous meningitis in children. Tubercle 1986;67(1):17-29.
37. Ramesh V, Misra RS, Saxena U, Mukherjee A. Comparative efficacy of drug regimens in skin tuberculosis. Clinical and Experimental Dermatology 1991;16(2):106-9.
38. Santha T, Nazareth O, Krishnamurthy MS, Balasubramanian R, Vijayan VK, Janardhanam B, et al.Treatment of pulmonary tuberculosis with short course chemotherapy in south India--5-year follow up. Tubercle 1989;70(4):229-34.
39. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis.. The American Review of Respiratory Diseases. 1985;132(2):374-8.
40. Swaminathan S, Raghavan A, Duraipandian M, Kripasankar AS, Ramachandran P. Short-course chemotherapy for paediatric respiratory tuberculosis: 5-year report. International Journal of Tuberculosis and Lung Disease 2005;9(6):693-6.
41. Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. International Journal of Tuberculosis and Lung Disease 2002;6(1):3-10.
42. Teo SK, Tan KK, Khoo TK. Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. Annals of the Academy of Medicine, Singapore 2002;31(2):175-81.
43. Tuberculosis Chemotherapy Centre, Madras . A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bulletin of the World Health Organization 1970;43(1):143-206.
44. Tuberculosis Research Centre. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 1997;1(6):509-17.
45. WHO Collaborating Centre for Tuberculosis Chemotherapy. A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. 1. First report: The results at 12 months. Bulletin of the World Health Organization 1971;45(5):573-93.
46. WHO Collaborating Centre For Tuberculosis Chemotherapy. A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. 2. Second report: the results from 12 to 24 months. Bulletin of the World Health Organization 1973;48(2):155-65.
47. Abernathy RS, Dutt AK, Stead WW, MoersDJ . Short-course chemotherapy for tuberculosis in children. Pediatrics 1983;72(6):801-6.
48. Acocella G. The use of fixed dose combinations in antituberculous chemotherapy. Rationale for their application in daily, intermittent and pediatric regimens. Bulletin of the International Union against Tuberculosis and Lung Disease 1990;65(2-3):77-83.
49. Amdekar Y. Changes in the management of tuberculosis. Indian Journal of Pediatrics 2009;76(7):739-42.
50. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al.GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
51. Beyers N, Gie RP, Zietsman HL, Kunneke M, Hauman J, Tatley M, et al.The use of a geographical information system (GIS) to evaluate the distribution of tuberculosis in a high-incidence community. South African Medical Journal 1996;86(1):40-4.
52. Biddulph J, Kokoha V, Sharma SS. Short course chemotherapy in childhood tuberculosis. Journal of Tropical Pediatrics 1988;34(1):20-3.
53. Biddulph J. Short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal 1990;9(11):794-801.
54. Brent AJ, Anderson ST, Kampmann B. Childhood tuberculosis: out of sight, out of mind?. Transactions of the Royal Society of Tropical Medicine and Hygiene 2008;102(3):217-8.
55. Centers for Disease Control and Prevention. Tuberculosis morbidity - United States, 1994. MMWR. Morbidity and mortality weekly report 1995;44(20):387-9, 395.
56. Chang KC, Leung CC, Grosset J, Yew WW. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011;66(11):997-1007.
57. Chauhan LS, Arora VK. Formulation of guidelines for diagnosis and treatment of paediatric TB cases under RNTCP. Indian Journal of Tuberculosis 2004;51(1):102-5.
58. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al.The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 2003;163(9):1009-21.
59. Crofton J, Horne N, Miller F. Clinical tuberculosis. 2nd Edition. London: Macmillan Education, 1999.
60. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Chichester: John Wiley & Sons, Available from www.cochrane-handbook.org.
61. Dickinson JM, Mitchison DA. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 1966;47(4):370-80.
62. Donald PR, Schaaf HS. Old and new drugs for the treatment of tuberculosis in children. Paediatric Respiratory Reviews 2007;8(2):134-41.
63. Donald PR. The treatment of tuberculosis in childhood. South African Medical Journal 2007;97(10 Pt 2):992-4.
64. Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis 2008;88(Suppl 1):S75-83.
65. Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatric Reports 2011;3(2):e16.
66. European Union ad hoc group for the development of implementing guidelines for Directive 2001/20/EC . European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. European Journal of Health Law 200;15(2):223-50.
67. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADE Profiler. 3.6 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2013.
68. Graham SM, Gie RM, Schaaf HS, Coulter JB, Espinal MA, Beyers N. Childhood tuberculosis: clinical research needs. International Journal of Tuberculosis and Lung Disease 2004;85(5):648-57.
69. Heymann SJ, Brewer TF, Wilson ME, Colditz GA, Fineberg HV. Pediatric tuberculosis: what needs to be done to decrease morbidity and mortality. Pediatrics 2000;106(1):e1.
70. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
71. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.
73. Hill S, Regondi L, Grzemska M, Matirua R. Children and tuberculosis medicines: bridging the research gap. Bulletin of the World Health Organization 2008;86(9):658.
74. Indian Academy of Pediatrics (IAP) Working Group. Treatment of childhood tuberculosis: consensus statement of IAP Working Group. Indian Pediatrics 1997;34(12):1093-6.
75. Indian Academy of Pediatric (IAP), Working group on tuberculosis. Consensus statement on childhood tuberculosis. Indian Pediatrics 2010;47(1):41-55.
76. International Institute for Population Sciences (IIPS) and Macro International. National Family Health Survey (NFHS-3), 2005-06: India. National Family Health Survey-3 2007; Vol. 1:411.
77. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
78. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282(11):1054-60.
79. Kant L. Childhood tuberculosis: increasing but neglected. Indian Journal of Tuberculosis 2001;48(1):1-2.
80. Kiper N, Göçmen A, Dilber E, Ozçelik U. Effectiveness of short-course, intermittent chemotherapy for tuberculosis in children. Clinical Pediatrics 1998;37(7):433-6.
81. Kiser JJ, Zhu R, D'Argenio DZ, Cotton MF, Bobat R, McSherry GD, et al.Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Therapeutic Drug Monitoring 2012;34(4):446-51.
82. Langendam MW, van der Werf MJ, Huitric E, Manissero D. Prevalence of inappropriate tuberculosis treatment regimens: a systematic review. European Respiratory Journal 2012;39(4):1012-20.
83. Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of randomized trials published world-wide -- the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library. Emerging Themes in Epidemiology 2008;5(13):1-13.
84. Magdorf K, Detjen AK. Proposed management of childhood tuberculosis in low-incidence countries. European Journal of Pediatrics 2008;167(8):927-38.
85. Mandalakas AM, Starke JR. Current concepts of childhood tuberculosis. Seminars in Pediatric Infectious Diseases 2005;16(2):93-104.
86. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al.The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. International Journal of Tuberculosis and Lung Disease 2004;8(4):392-402.
87. Marais BJ, Pai M. Recent advances in the diagnosis of childhood tuberculosis. Archives of Disease in Childhood 2007;92(5):446-52.
88. Marais BJ, Schaaf HS. Childhood tuberculosis: An emerging and previously neglected problem. Infectious Diseases Clinics of North America 2010;24(3):729-49.
89. Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Methodological standards for the conduct of new Cochrane Intervention Reviews. Version 2.1, 8 December 2011 Available from http://www.editorial-unit.cochrane.org/sites/editorial-unit.cochrane.org/files/uploads/MECIR_conduct_standards%202.1.pdf.
90. Menon PR, Lodha R, Sivanandan S, Kabra SK. Intermittent or daily short course chemotherapy for tuberculosis in children: meta-analysis of randomized controlled trials. Indian Pediatrics 2010;47(1):67-73.
91. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al.Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes:A systematic review and meta-analysis. PLoS Medicine 2009;6(9):e1000146.
92. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: ]
93. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. International Journal of Tuberculosis and Lung Disease 2004;8(5):636-47.
94. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet Infectious Diseases 2008;8(8):498-510.
95. Reis FJ, Bedran MB, Moura JA, Assis I, Rodrigues ME. Six-month isoniazid-rifampin treatment for pulmonary tuberculosis in children. American Review of Respiratory Disease 1990;142(5):996-9.
96. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
97. Revised National Tuberculosis Control Programme. National guidelines on diagnosis and treatment of pediatric tuberculosis. http://tbcindia.nic.in/documents.html. Directorate General of Health Services. Ministry of Health and Family Welfare, (accessed 1 November 2012).
98. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, et al.Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Archives of Disease in Childhood 2005;90(6):614-8.
99. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of antituberculosis drug resistance from the Western Cape province of South Africa- an upward trend. American Journal of Public Health 2009;99(8):1486-90.
100. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Hanbook for Systematic Reviews of Intervention. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
101. Seddon JA, Warren RM, Enarson DA, Beyers N, Schaaf HS. Drug-resistant tuberculosis transmission and resistance amplification within families. Emerging Infectious Diseases 2012;18(8):1342-5.
102. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infectious Diseases 2003;3(10):624-32.
103. Snider DE, Rieder HL, Combs D, Bloch AB, Hayden CH, Smith MH. Tuberculosis in children. Pediatric Infectious Disease Journal 1988;7(4):271-8.
104. Starke JR, Taylor-Watts KT. Tuberculosis in the pediatric population of Houston, Texas. Pediatrics 1989;84(1):28-35.
105. Starke JR, Taylor-Watts KT. Six month chemotherapy of intrathoracic tuberculosis in children. American Reviews of Respiratory Diseases 1989;139(suppl):A314.
106. Starke JR. Multidrug therapy for tuberculosis in children. Pediatric Infectious Disease Journal 1990;9(11):785-93.
107. Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 1: Introduction and diagnosis of tuberculosis in children. International Journal of Tuberculosis and Lung Disease 2006;10(10):1091-7.
108. Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 2: Anti-tuberculosis treatment in children. International Journal of Tuberculosis and Lung Disease 2006;10(11):1205-11.
109. Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 3: Management of TB in the HIV-infected child. International Journal of Tuberculosis and Lung Disease 2006;10(12):1331-6.
110. Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 4: Childhood contact screening and management. International Journal of Tuberculosis and Lung Diseases 2007;11(1):12-5.
111. Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, et al.Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrobrobial Agents and Chemotherapy 2011;55(12):5560-7.
112. Varudkar BL. Short-course chemotherapy for tuberculosis in children. Indian Clinical Journal of Pediatrics 1985;52(419):593-7.
113. Walls T, Shingadia D. Global epidemiology of paediatric tuberculosis. Journal of Infection 2004;48(1):13-22.
114. World Health Organization. Communicable diseases: tuberculosis, fact sheets on TB, TB and children. http://www.searo.who.int/EN/Section10/Section2097/Section2106_10681.htm (accessed 27 April 2009).
115. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008).
116. World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010.
117. World Health Organization. Annex 1 - Evidence summary tables. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010.
118. World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization, 2012.